<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8006959</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2310</journal-id>
<journal-id journal-id-type="nlm-ta">Neurochem Int</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurochem. Int.</journal-id>
<journal-title-group>
<journal-title>Neurochemistry international</journal-title>
</journal-title-group>
<issn pub-type="ppub">0197-0186</issn>
<issn pub-type="epub">1872-9754</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29800604</article-id>
<article-id pub-id-type="pmc">6250597</article-id>
<article-id pub-id-type="doi">10.1016/j.neuint.2018.05.013</article-id>
<article-id pub-id-type="manuscript">NIHMS971019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Blockade and Reversal of Swimming-induced Paralysis in <italic>C. elegans</italic> by the Antipsychotic and D2-type Dopamine Receptor Antagonist Azaperone</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Refai</surname>
<given-names>Osama</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blakely</surname>
<given-names>Randy D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University</aff>
<aff id="A2">
<label>2</label>Brain Institute, Jupiter, Florida, USA 33458</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence: Randy D. Blakely, Ph.D., MC-17, Room 109, Florida Atlantic University Brain Institute, 5353 Parkside Drive, Jupiter, FL 33458, TEL: 561-799-8100, <email>rblakely@health.fau.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>28</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2020</year>
</pub-date>
<volume>123</volume>
<fpage>59</fpage>
<lpage>68</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuint.2018.05.013-->
<abstract>
<p id="P2">The catecholamine neurotransmitter dopamine (DA) exerts powerful modulatory control of physiology and behavior across phylogeny. Perturbations of DA signaling in humans are associated with multiple neurodegenerative and behavioral disorders, including Parkinson’s disease, attention-deficit/ hyperactivity disorder, addiction and schizophrenia. In the nematode <italic>C. elegans</italic>, DA signaling regulates mating behavior, learning, food seeking and locomotion. Previously, we demonstrated that loss of function mutations in the <italic>dat-1</italic> gene that encodes the presynaptic DA transporter (DAT-1) results in a rapid cessation of movement when animals are placed in water, termed Swimming Induced Paralysis (Swip). Mutations in genes supporting DA biosynthesis, vesicular packaging and DA signaling suppresses Swip in <italic>dat-1</italic> animals, consistent with paralysis as arising from excessive DA signaling at the extrasynaptic D2-type DA receptor DOP-3. Although animals grown on the vesicular monoamine transporter antagonist reserpine diminish Swip, the drug must be applied chronically, can impact the signaling of multiple biogenic amines, and has been reported to have penetrant, off-target actions. Here, we demonstrate that the antipsychotic drug azaperone potently and rapidly suppresses Swip behavior in either <italic>dat-1</italic> mutants, as well as in wildtype animals treated with the DAT-1 antagonist nisoxetine, with genetic experiments consistent with DOP-3 antagonism as the mechanism of Swip suppression. Reversal of Swip in previously paralyzed <italic>dat-1</italic> animals by azaperone application demonstrates an otherwise functionally-intact swimming circuit in these mutants. Finally, whereas azaperone suppresses DA-dependent Swip, the drug fails to attenuate the DA-independent paralysis induced by βPEA, aldicarb or genetic disruption of γ-aminobutyric acid (GABA) signaling. We discuss our findings with respect to the use of azaperone as a potent and selective tool in the identification and analysis of presynaptic mechanisms that regulate DA signaling.</p>
</abstract>
<kwd-group>
<kwd>dopamine</kwd>
<kwd>azaperone</kwd>
<kwd>D2-type dopamine receptor</kwd>
<kwd>Swip</kwd>
<kwd>
<italic>C. elegans</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>